742 related articles for article (PubMed ID: 31229470)
1. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
3. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N
Brain; 2015 Oct; 138(Pt 10):2964-73. PubMed ID: 26209314
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease.
Wilson H; Giordano B; Turkheimer FE; Chaudhuri KR; Politis M
Neuroimage Clin; 2018; 18():630-637. PubMed ID: 29845011
[TBL] [Abstract][Full Text] [Related]
6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
7. The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia.
Breza M; Koutsis G; Karadima G; Potagas C; Kartanou C; Papageorgiou SG; Paraskevas GP; Kapaki E; Stefanis L; Panas M
Neurosci Lett; 2018 Apr; 672():136-139. PubMed ID: 29233723
[TBL] [Abstract][Full Text] [Related]
8. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
[TBL] [Abstract][Full Text] [Related]
9. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.
Maillet A; Krack P; Lhommée E; Météreau E; Klinger H; Favre E; Le Bars D; Schmitt E; Bichon A; Pelissier P; Fraix V; Castrioto A; Sgambato-Faure V; Broussolle E; Tremblay L; Thobois S
Brain; 2016 Sep; 139(Pt 9):2486-502. PubMed ID: 27538418
[TBL] [Abstract][Full Text] [Related]
10. Extrastriatal
Nicastro N; Garibotto V; Burkhard PR
BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
[TBL] [Abstract][Full Text] [Related]
11. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
12. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal
Pasquini J; Ceravolo R; Brooks DJ; Bonuccelli U; Pavese N
Parkinsonism Relat Disord; 2020 Aug; 77():170-175. PubMed ID: 30981664
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
14. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A; Concha-Marambio L; Lafontant DE; Farris CM; Ma Y; Urenia PA; Nguyen H; Alcalay RN; Chahine LM; Foroud T; Galasko D; Kieburtz K; Merchant K; Mollenhauer B; Poston KL; Seibyl J; Simuni T; Tanner CM; Weintraub D; Videnovic A; Choi SH; Kurth R; Caspell-Garcia C; Coffey CS; Frasier M; Oliveira LMA; Hutten SJ; Sherer T; Marek K; Soto C;
Lancet Neurol; 2023 May; 22(5):407-417. PubMed ID: 37059509
[TBL] [Abstract][Full Text] [Related]
15. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.
Kohl Z; Ben Abdallah N; Vogelgsang J; Tischer L; Deusser J; Amato D; Anderson S; Müller CP; Riess O; Masliah E; Nuber S; Winkler J
Neurobiol Dis; 2016 Jan; 85():206-217. PubMed ID: 26523794
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease.
Deusser J; Schmidt S; Ettle B; Plötz S; Huber S; Müller CP; Masliah E; Winkler J; Kohl Z
J Neurochem; 2015 Nov; 135(3):589-97. PubMed ID: 26201615
[TBL] [Abstract][Full Text] [Related]
17. Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation of Essential Tremor and Parkinsonism.
Lee H; Sung YH; Hwang KH
Curr Med Imaging; 2023; 19(9):1041-1051. PubMed ID: 36734891
[TBL] [Abstract][Full Text] [Related]
18. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
[TBL] [Abstract][Full Text] [Related]
20. Investigation of serotonergic Parkinson's disease-related covariance pattern using [
Fu JF; Klyuzhin I; Liu S; Shahinfard E; Vafai N; McKenzie J; Neilson N; Mabrouk R; Sacheli MA; Wile D; McKeown MJ; Stoessl AJ; Sossi V
Neuroimage Clin; 2018; 19():652-660. PubMed ID: 29946508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
